Levy says
Body fat estimate dropped from 13.0% to 11.3% (circumference-based)
I think this is a genuinely useful development, reflecting the industry actually responding to a real, emerging clinical need rather than manufacturing a trend, but I also think patients deserve a clear-eyed explanation of what these ingredients can and cannot realistically achieve given the mechanism potentially at play
We dont have exact numbers of how much weight people were losing, especially when they ingested the thyroid hormone, but the results were good enough that people kept buying them
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has an even larger molecular structure than semaglutide alone
Jos Manuel Carrascosa has participated as PI/SI and/or guest presenter and/or advisor for Almirall, Janssen, Abbvie, UCB, Boehringer-Ingelheim, Lilly, Novartis, Amgen, BMS, and Sandoz